The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...

For children with severe Crohn disease, upadacitinib offers an effective induction therapy, but its benefits must be ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in ...